ODE Annual Report Shows Faster PMA Reviews, Fewer IDE Submissions
This article was originally published in The Gray Sheet
Executive Summary
A 22% decrease in the number of investigational device exemption submissions received by CDRH in FY 2003 could portend a future decline in PMA submissions
You may also be interested in...
On FDA Critical Path, Device Industry Demands Independence From Pharma
AdvaMed objects to FDA's characterization of the device industry's product pipeline as endangered, asserting that the agency's model for determining development timelines is skewed toward drugs
On FDA Critical Path, Device Industry Demands Independence From Pharma
AdvaMed objects to FDA's characterization of the device industry's product pipeline as endangered, asserting that the agency's model for determining development timelines is skewed toward drugs
McClellan’s FDA Legacy? Decisive Role In Product Development Priorities
FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress